1.
Seida JC, Schouten JR, Mousavi SS, et al. First- and Second-Generation Antipsychotics for Children and Young Adults. Rockville, MD: Agency for Healthcare Research and Quality; Feb, 2012. (Comparative Effectiveness Review No. 39). (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021.) AHRQ Publication No 11(12)-EHC077-EF.
2.
Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009 Jan 3;373(9657):31–41. [PubMed: 19058842]
3.
Haddad PM, Das A, Keyhani S, et al. Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons. J Psychopharmacol. 2011 Nov 5 [PubMed: 22057019]
4.
Margetic B, Aukst-Margetic B. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiol Drug Saf. 2010 May;19(5):429–35. [PubMed: 20306454]
5.
Zito JM, Safer DJ, dosReis S, et al. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000;238(8):1025–30. [PubMed: 10697062]
6.
Zito JM, Safer DJ, DosReis S, et al. Psychotropic practice patterns for youth: a 10 year perspective. Arch Pediatric Adolesc Med. 2003;157(1):17–25. [PubMed: 12517190]
7.
Zito JM, Safer DJ, de Jong-van den Berg LT, et al. A three-country comparison of psychotropic medication prevalence in youth. Child Adolesc Psychiatry Ment Health. 2008;121(1):26. [PMC free article: PMC2569908] [PubMed: 18817536]
8.
Zito JM, Safer DJ, Sai D, et al. Psychotropic medication patterns among youth in foster care. Pediatrics. 2008;121(1):e157–e63. [PubMed: 18166534]
9.
Pathak SAS, Danielyan A, et al. Psychotropic utilization and psychiatric presentation of hospitalized very young children. J Child Adolesc Psychopharmacol. 2004;14(3):433–42. [PubMed: 15650500]
10.
Kuehn BM. Studies shed light on risks and trends in pediatric antipsychotic prescribing. JAMA. 2010 May 19;303(19):1901–3. [PubMed: 20483961]
11.
Owens DK, Lohr KN, Atkins D, et al. Grading the strength of a body of evidence when comparing medical interventions. Methods guide for effectiveness and comparative effectiveness reviews. 2008 [PubMed: 21433399]
12.
Cohen J. A power primer. Psychol Bull. 1992 Jul;112(1):155–9. [PubMed: 19565683]
13.
Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009 Oct 28;302(16):1765–73. [PMC free article: PMC3055794] [PubMed: 19861668]
14.
Lenth RV. Java Applets for power and sample size [Computer software]. 2006–9. [Accessed December 5, 2011]. Available at: http://www​.stat.uiowa.edu/~rlenth/Power.
15.
Tohen M, Kryzhanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry. 2007 Oct;164(10):1547–56. [PubMed: 17898346]
16.
Haas M, Delbello MP, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009 Nov;11(7):687–700. [PubMed: 19839994]
17.
Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med. 2000 Nov 30;19(22):3127–31. [PubMed: 11113947]
18.
Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand. 2008 Jun;117(6):412–9. [PubMed: 18479317]
19.
Brant R. Inference for proportions: comparing two independent samples [Computer software]. [Accessed December 6, 2011]. Available at: http://www​.stat.ubc.ca​/~rollin/stats/ssize/b2.html.